We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.50 | -0.34% | 1,604.50 | 1,604.00 | 1,605.00 | 1,615.50 | 1,599.50 | 1,611.50 | 4,229,866 | 16:35:09 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.40 | 66.04B |
Date | Subject | Author | Discuss |
---|---|---|---|
11/1/2020 19:33 | The WPCT threads went into some detail about this. The areas which looked most dodgy were the guernsey listings to get round the percentage of unlisteds, and the non declaration that he sold a lot of his holding in WPCT without mentioning it as he apparently wasnt a PDMR. HL also have questions to answer. I'm in the process of closing my HL account partially because of it. The £350 yearly platform fees is the main reason. Unfortunately his huge premier league remuneration for his amateur stock picking wasnt illegal. | dr biotech | |
11/1/2020 18:02 | Dr B - my sentiments entirely, however, unfortunately the FCA don't insist on funds having an Investment/Trading Book Policy Statement or on their individual company and sector exposures being adhered to. Let alone an acceptable revaluation methodology which should have been rigorously monitored. These requirements, which are made on banks, would have saved joe public and also exposed him for the charlatan that he really was. I feel sorry for the poor investors who fell foul of his ego and p*ss poor regulatory attention to detail. Surely he has to be culpable in respect of his movement away from the initial Investment Terms of the Funds which appears also to have been ignored? | ianood | |
11/1/2020 11:39 | Seemed to recall he had a big weighting in Astra Zeneca too - should have held on to that as well!! | panshanger1 | |
11/1/2020 09:13 | Woodford should have stayed with GSK and not bought into the early stage biotiddlers that few really understand. At one point I had 25% of my portfolio in his various funds. Fortunately I sold out when he took such a large holding in prothena and realised he’d lost the plot. I’m really surprised the fca aren’t after him with some of the things he did. Your dividend TM is worth more than my entire holding. GSK isn’t one of my top 10 though. | dr biotech | |
10/1/2020 10:13 | I'm expecting some action ahead of this: 5 February 2020 (announcement of Q4 2019 results) | tradermichael | |
09/1/2020 10:24 | I can afford Black Forrest gateau to-day :-) | sicker | |
09/1/2020 10:08 | Wow, something was driving the price this morning. Thought it was all those dividends being reinvested (mine is for some cakes and some more GSK shares when the price relaxes a bit ….. ;0) ) | tradermichael | |
09/1/2020 10:05 | Morning everyone.. FWIW +++ SOCGEN KEEPS GLAXOSMITHKLINE 'BUY' RATING - PRICE TARGET 2300 (2200) PENCE +++ | philanderer | |
09/1/2020 10:01 | LOL …. ;0) | tradermichael | |
09/1/2020 09:57 | Cakes are on you then | badtime | |
09/1/2020 09:52 | Yes, I received £7673 in my AJ Bell accounts this morning …. ;0) | tradermichael | |
09/1/2020 08:39 | First GSK dividend of the year is paid today | gateside | |
08/1/2020 15:23 | Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET) Prior to joining ViiV Healthcare as its CEO, Waterhouse spent more than 20 years climbing the GSK corporate ladder. Early in her career, she had stints in sales and marketing, and she spent four years in R&D working on early-target product profiles and commercial analytics around new assets. “I even did a two-year rotation through HR,” she shares. “After all, the biopharmaceutical industry is here to serve patients, and the best way to do that is by having the right people in the right roles, so you can focus on unlocking their potential.” Following these London- based positions, she took on the role of country manager for Australia and New Zealand. Next it was back to the U.K. as head of central and eastern Europe, a 22-country responsibility. Then she spent three years in Philadelphia, first as the business unit head of GSK’s U.S. vaccine business, then heading up the company’s U.S. primary care business. | tradermichael | |
08/1/2020 09:57 | Final year end divi xd is 20 Feb 20. A lovely 23p available for buyers till then ….. ;0) | tradermichael | |
08/1/2020 09:34 | SP back to divi buying levels or even lower | abdullla | |
08/1/2020 09:28 | One example where you really could say of many of Woodford's punters, "Where are the customers' yachts?" ............... Still, you pays yer money etc. etc. | keyno | |
07/1/2020 15:54 | Then what happened to them and where are they now ? | abdullla | |
07/1/2020 15:36 | what about their poor clients?? | lippy4 | |
07/1/2020 15:27 | Disgraced money manager Neil Woodford and his business partner pocketed £13.8 million in dividends in the financial year before the crisis that led to the demise of his fund empire. The dividend haul was revealed in accounts filed with Companies House for Woodford Investment Management for the last full financial year before the suspension of the flagship equity income fund in June. Mr Woodford received nearly two-thirds of the payout – around £9 million – for the year to March 31, thanks to his 65% ownership of Woodford Investment Management. Chief executive Craig Newman picked up £4.8 million. The pair also bagged £36.5 million the previous year. | tradermichael | |
06/1/2020 09:01 | fwiw: NOVARTIS has raised U.S. prices on nearly 30 drugs including psoriasis treatment Cosentyx and multiple sclerosis medicine Gilenya. Most of those increases were in the range of 5.5% to 7%. | alphorn | |
05/1/2020 17:09 | GlaxoSmithKline PLC raised the prices on more than two dozen different therapies, although none by more than by 5%. That includes its shingles vaccine, Shingrix, which sold about $1.7 billion globally in the first nine months of 2019. A Glaxo spokeswoman confirmed the increases and said net prices for its U.S. products fell about 3.4% on average annually the past five years. | tradermichael | |
03/1/2020 16:27 | You cant touch me I am part of NHS . | abdullla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions